TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05678426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive an optional exercise programme and motivational coaching over the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting with ketogenic supplement
Description: The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
Study: NCT04650581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: 400 mg PO QD days 1-21 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: 500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO QD days 1-21 every 28 days
Study: NCT05918445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: IV infusion
Study: NCT04681144

Intervention type: DRUG
Intervention: Radium-223-dichloride (Xofigo, BAY88-8223)
Description: Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
Study: NCT05973864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab injection
Description: On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: 1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local radiotherapy
Description: Local radiotherapy will be performed as per standard practice if indicated.

Intervention type: RADIATION
Group type: OTHER
Intervention: Local radiotherapy
Description: Local radiotherapy will be performed as per standard practice if indicated.
Study: NCT05746988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash gargling
Description: 15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouthwash gargling
Description: 15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
Study: NCT05532969

Intervention type: OTHER
Intervention: stressors
Description: Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
Study: NCT05945888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3000202
Description: Placebo matching BI 3000202
Study: NCT05748821

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi Personal Tourniquet Systems
Description: Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi Personal Tourniquet Systems
Description: Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delfi Personal Tourniquet Systems
Description: Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
Study: NCT05669365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Ecosystem
Description: Applying the principles of person-and-family centered and collaborative care to dementia, the Care Ecosystem (CE) offers proactive, protocol-guided phone- and web-based caregiver support, guidance, and care coordination that extends the reach of dementia primary and specialty care. Care is delivered primarily via the phone and web by unlicensed Care Team Navigators (CTNs), who are trained and supervised by a team of dementia specialists with nursing, social work, and pharmacy expertise. Care Protocols guide proactive, quality care that is documented in the electronic health record (EHR).~The CTN is an unlicensed, trained dementia care guide who served as the PWD's and caregiver's primary point of contact to the program under nurse supervision. Care team navigators respond to caregivers' immediate needs first, then screen for common problems and provide personalized support and standardized education using the care plan protocols.
Study: NCT05049863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol is commercially available.
Study: NCT05589441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: 10 mg salbutamol diluted to 2 ml with distilled water and inhaled as aerosolized for 15 min before the start of the hepatic-free phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.
Study: NCT05049863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is commercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is commercially available.
Study: NCT04812925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection with efgartigimod PH20 SC
Study: NCT05236036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given Orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given Orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given Orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given Orally (PO)
Study: NCT06065124

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery strategy
Description: Bariatric surgery including an intensive pre- and postoperative treatment scheme
Study: NCT05089292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative breast health education
Description: Health education program utilizing narrative messages to promote breast cancer screening in Chinese immigrant women will be delivered in a group format in the community
Study: NCT05947006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Patients in this arm will receive the standard care stablished in the emergency room after a febrile seizure, consisting of a medical assessment of the child, followed by 6 hours of supervision of the child and his parent in the waiting room, a reassessment of the child by the doctor, and finally they can return home
Study: NCT05119764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage is a form of physical therapy with the primary goal of accelerating lymphatic drainage.~In this study, the manual lymphatic drainage is applied by experienced physical therapists 5 days in a row for 30 minutes each; after and/or before the surgery.
Study: NCT05492409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-069
Description: Once a week as a subcutaneous injection.
Study: NCT05947006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONSULFE consultation
Description: In addition to the standard care, patients in this arm will receive a consultation managed by the pediatric nurse (CONSULFE) during the 6 hour supervision time in the waiting room
Study: NCT05622123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-Exendin-4
Description: PET/CT imaging after injection with 68Ga-NODAGA-exendin-4
Study: NCT06520137

Intervention type: PROCEDURE
Intervention: Tooth extraction
Description: Extraction of maxillary third molars

Intervention type: PROCEDURE
Intervention: Tooth extraction
Description: Extraction of maxillary third molars
Study: NCT05146375

Intervention type: BIOLOGICAL
Intervention: TGFBR2
Description: TGFBR2 mutation correlation with severity of the aortic disease. Blood sampling. Serum will be analysed by DNA sequencing to detect specific mutations involved in aneurysms.~Cutaneous biopsy. Fibroblast culture will be done to assess the transcriptome analysis.
Study: NCT05223517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted to 60-70mm in Ciliao and Huiyang, 6-10 mm in Shenmen and 10-20mm in other acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times (except for Ciliao) to achieve deqi sensation and manipulated every ten minutes during 20-minute maintenance in prone and supine position respectively.~Participants receive acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Hwato brand disposable placebo needles (with the handle identical to the needles in the acupuncture group and the body at a size 0.30 × 25 mm) and adhesive pads will be used. Acupoints of Ciliao, Huiyang, Shenshu, Guanyuan, Shuidao, Sanyinjiao, Zusanli, Taixi, Hegu, and Taichong will be used for every participants. Those with sleep or mood disorders will also use acupoints of Shangyintang, Shenmen and Neiguan. Those with tenderness points on the abdominal wall will also use Ashi points no more than five.~The needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrusted and twirled gently for 3 times to mimic real acupuncture. No manipulation will be conducted during 20-minute maintenance in prone and supine position respectively.~Participants receive sham acupuncture treatment three times a week in the first four weeks and twice a week in the last four weeks.
Study: NCT04837976

Intervention type: OTHER
Intervention: Semi-structured interviews and a consensus workshops using nominal group techniques.
Description: Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.

Intervention type: OTHER
Intervention: Semi-structured interviews and a consensus workshops using nominal group techniques.
Description: Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.

Intervention type: OTHER
Intervention: Semi-structured interviews and a consensus workshops using nominal group techniques.
Description: Stage 1 of the study includes individual remote semi-structured interviews (one per participant). Stage 2 involves taking part in a consensus workshop with around 7 other Parkinson's experts, consisting of patients, supportive individuals and healthcare professionals.
Study: NCT05445440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986371
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986371
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Specified dose on specified days
Study: NCT06033118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine ,oxaliplatin,anlotinib,Sintilimab
Description: Gemox chemotherapy（gemcitabine 1g/m2 ivgtt d1,d8 +oxaliplatin 85g/m2 ivgtt d1，q3w，anlotinib (8mg po d1-14 q3w )and Sintilimab (200mg ivgtt d1 q3w)
Study: NCT06340100

Intervention type: OTHER
Intervention: find association between vestibular impairment , cognitive fiunction with concussin
Description: SCOAT 6 is a standardized tool used for evaluating athletes suspected of having a concussion. It includes a variety of components such as symptom evaluation, cognitive assessment, balance evaluation, and a neck examination. it helps in assessing the severity of the injury, tracking recovery, and making return-to-play decisions. Dr. Robert Cantu, a prominent figure in sports concussion research, has proposed guidelines for the management of concussions. These guidelines typically involve recommendations for the evaluation, treatment, and return-to-play decisions for athletes who have sustained concussions
Study: NCT05772923

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Contact x-ray brachytherapy
Description: With contact x-ray brachytherapy an intraluminal radiation boost up to 90 Gy is applied to the primary rectal tumour, with minimal collateral damage to the surrounding normal tissues due to minimal penetration of the 50 kVolt therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local excision
Description: Local excision will basically be performed by the TAMIS-procedure (transanal minimally invasive surgery).
Study: NCT04768335

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive experiments' session
Description: The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive experiments' session
Description: The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
Study: NCT04790552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dinner
Description: Study subjects will consume a standardized ready-to-eat meal as dinner.
Study: NCT06522711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: A brief overview of all three virtual reality scenarios will be shown in a consolidated video prior to letting the participant select the preferred scenario. The participant's choice of scenario will then be documented. Once paravertebral blocks are completed and the participants are in supine position and the surgeon is ready to disinfect, the VR headset will be applied on the face of the participants in the intervention group and the chosen scenario will be started. If at any point the patient expresses a desire to stop using VR during the surgery, we will first offer them an alternate scenario. If they reiterate their willingness to stop, with or without having experienced the new scenario, the headset will be removed for the remainder of the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care in anesthesia with patient-controlled sedation.
Study: NCT04790552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dinner
Description: Study subjects will consume a standardized ready-to-eat meal as dinner.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dinner
Description: Study subjects will consume a standardized ready-to-eat meal as dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dinner
Description: Study subjects will consume a standardized ready-to-eat meal as dinner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Subjects will be asked to fast overnight for approximately 15 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Subjects will be asked to fast overnight for approximately 15 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Subjects will be asked to fast overnight for approximately 15 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Subjects will be asked to fast overnight for approximately 15 hours.
Study: NCT04094948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol
Description: 20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
Study: NCT04996329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early health warning intervention
Description: early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early health warning intervention
Description: early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
Study: NCT05811325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping without craniosacral therapy
Description: The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotaping with craniosacral therapy
Description: The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
Study: NCT06050980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK40118
Description: Oral administration, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK40118
Description: Oral administration, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK40118
Description: Oral administration, QD
Study: NCT04380155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity cycling trials of different duration (30, 60 and 120 min)